Kamada Receives Orphan Drug Status For Glassia Treatment

October 30, 2014 | Kamada has been awarded orphan drug status from the US Food & Drug Administration for Glassia, a drug to treat Graft-versus-host-disease (GVHD). When a company receives orphan drug status they are able to receive grant money, tax credits and seven years of marketing exclusivity, with the possibility for an extended regulatory process. Preliminary human and animals studies show that Glassia may be able to treat and reduce the severity of of GVHD, one of the key complications that occurs in stem cell transplantation. Kamida is a biopharmaceutical company based in Israel co-founded by CEO David Tsur.